{
  "docId": "019de077-19d1-772e-933a-c7f1c42d9b04",
  "docSlug": "d223628377f56d072b5dbf426c21baf1",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 42,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 80,
  "notes": "Data cut-off: 8 Aug 2023. Includes detailed breakdown of response by mutation type and prior treatment history.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-19d1-772e-933a-c7f1c42d9b04/19",
  "deckHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04",
  "deckJsonHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04.json",
  "deckAnchorHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "disclaimer",
      "text": "Data cut-off: 8 Aug 2023. Response-evaluable patients with ALK+ NSCLC. 1G, 1st generation ALK TKI (crizotinib); 2G, 2nd generation ALK TKI (alectinib, brigatinib, or ceritinib); CNS, central nervous system; NE, not evaluable; ORR, objective response rate; PD, progressive disease, PR, partial response, RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1; SD, stable disease, TKI, tyrosine kinase inhibitor. a Out of 16 patients harboring presumed compound ALK mutations, 8 have evidence of cis-allelic configuration by central ctDNA analysis. b Includes patients with single G1202R mutation (n=5) and G1202R with compound mutations (n=12; 6 with evidence of cis-allelic configuration). c Includes 4 patients with ongoing partial responses pending confirmation. d Three patients discontinued treatment due to clinical progression without post-baseline radiographic assessment. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a1c523b-03a6-4318-a90c-15959cfbcdcb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "table",
      "text": "Table showing ORR and response counts (PR, SD, PD, NE) across patient cohorts including CNS metastases, resistance mutations, and prior TKI history.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad641007-cf64-4c10-82bb-3751081348df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "Preliminary Activity: Tumor Response Across Heavily Pretreated Patient Populations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c998edd7-e421-4504-9534-20fa5105b794",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}